06118 AUSTAR
- 0.730
- -0.020-2.67%
AUSTAR News
The Market Doesn't Like What It Sees From Austar Lifesciences Limited's (HKG:6118) Revenues Yet As Shares Tumble 34%
Unfortunately for some shareholders, the Austar Lifesciences Limited (HKG:6118) share price has dived 34% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last m
奧星生命科技：2023年報
Aoxing Life Technology (06118.HK)'s total annual revenue was about 1,764 billion yuan, a year-on-year decrease of about 18.2%
Gelonghui, March 26, 丨 Aoxing Life Technology (06118.HK) announced that for the year ended December 31, 2023, the Group's total revenue was approximately RMB 1,763.7 million, a decrease of about 18.2% compared to the year ended December 31, 2022. This was mainly due to reduced revenue from the Fluid and Bioprocess Systems, Clean Room and Automated Control and Monitoring Systems and Life Science Consumables business segments, partially offset by increased revenue from the Powder Solids Systems, Pharmaceutical Equipment Distribution and Agency business segments. The Group recorded an annual loss of RMB 151.3 million in the current year compared to 2
Aoxing Life Technology (06118) announced the 2023 annual results. Shareholders' share loss of 113 million yuan changed from profit to loss year-on-year
According to the Zhitong Finance App, Aoxing Life Technology (06118) disclosed its 2023 annual results. The group achieved revenue of 1,764 billion yuan (RMB, same below) during the reporting period, a year-on-year decrease of 18.23%. Gross profit of 336 million yuan, a year-on-year decrease of 31.25%. The owners of the company should have accounted for a loss of 113 million yuan during the year, changing from profit to loss over the same period last year. Loss of $0.22 per share. During the reporting period, the group's order volume decreased by about 32.7% compared to 2022, due to a decrease in the number of projects and delays in project progress due to a slowdown in capital expenditure investment after recovering from the COVID-19 pandemic.
AUSTAR: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Aoxing Life Technology (06118.HK) held a board meeting on March 26 to consider and approve annual results
Glonghui March 14 | Aoxing Life Technology (06118.HK) announced that the board of directors meeting will be held on March 26, 2024 (Tuesday) to consider and approve (including) the Group's annual results for the year ended 31 December 2023 and the proposed payment of a final dividend (if any).
Investors Give Austar Lifesciences Limited (HKG:6118) Shares A 27% Hiding
Austar Lifesciences Limited (HKG:6118) shares have had a horrible month, losing 27% after a relatively good period beforehand.
Aoxing Life Technology [06118] now reports HK$1.98, an increase of 13.14%
As of 12:04, Aoxing Life Technology [06118] reported HK$1.98, up HK$0.23 or 13.14% from yesterday's closing price, with a turnover of HK$912,000. Today's high price was HK$1.89 and the lowest price was HK$1.7. Based on yesterday's closing price, the 10-day average price was HK$1.85, and the 50-day average price was HK$1.79. The current price-earnings ratio was 9.15 times, and the 14-day strength and weakness index was reported at 42.28.
Austar Lifesciences Limited (HKG:6118) Stock Rockets 31% But Many Are Still Ignoring The Company
Those holding Austar Lifesciences Limited (HKG:6118) shares would be relieved that the share price has rebounded 31% in the last thirty days, but it needs to keep going to repair the recent damage it
Austar Lifesciences to Swing to Loss; Shares Drop
Shares of Austar Lifesciences (HKG:6118) dropped some 8% in recent trade after the firm said it expects an attributable loss of about 110 million yuan for the fiscal year through December 2023, as com
Selected Announcements | China Merchants Bank's net profit last year exceeded 146.6 billion yuan; China Telecom's 5G users increased by 50.7 million last year
Haifeng International issued a profit warning. The profit due to shareholders in 2023 is expected to be about 530 million US dollars, down about 73% from the previous year; Zero Sports Auto will issue H shares and domestic shares to raise up to 600 million yuan.
Aoxing Life Technology (06118.HK) Profit Alert: Expected annual loss of about 110 million yuan
Gelonghui, January 19, 丨 Aoxing Life Technology (06118.HK) announced that the company expects to record a loss attributable to the company owner of about RMB 110 million for the year ended December 31, 2023, compared to the profit attributable to the company owner of approximately RMB 87 million for the year ended December 31, 2022. Expected losses are mainly due to: (1) In the 2023 fiscal year, H+E Pharma GmbH and S-tec GmbH (the company's then indirect non-wholly-owned subsidiary) filed for bankruptcy on August 3, 2023
Austar Lifesciences Hires New Auditor
Austar Lifesciences (HKG:6118) has hired Moore CPA as its auditor effective today, Nov. 17. Moore will fill the casual vacancy arising from the termination of PricewaterhouseCoopers' (PwC) services. E
AUSTAR: 2023 Interim Report
Austar Lifesciences Swings to Loss in H1
Austar Lifesciences (HKG:6118) incurred a loss attributable to owners of 39.9 million yuan for the first half, swinging from the year-ago attributable profit of 45.8 million yuan. Loss per share stood
AUSTAR: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Austar Lifesciences Limited's (HKG:6118) Largest Shareholder, CEO Kwok Keung Ho Sees Holdings Value Fall by 30% Following Recent Drop
Key Insights Austar Lifesciences' significant insider ownership suggests inherent interests in company's expansion Kwok Keung Ho owns 67% of the company Using data from company's past performance
AUSTAR: NOTICE OF BOARD MEETING
Austar Lifesciences Expects Higher Loss in H1
Austar Lifesciences (HKG:6118) updated its guidance for the first half, and now expects to swing to a loss of 40 million yuan in the first half from a profit of 45.8 million yuan in the year-ago perio
Aoxing Life Technology (06118.HK) updates earnings alert: Expected net loss of 40 million yuan in the first half of the year to year-on-year profit and loss
Glonway, August 3, 丨Aoxing Life Technology (06118.HK) announced that according to a preliminary assessment of the Group's unaudited comprehensive management accounts for the six months ended June 30, 2023 and the data currently available to the board of directors, it is expected that the Group will record losses due to company owners of about RMB 40 million for the six months ending June 30, 2023, while the profit due to company owners for the six months ended June 30, 2022 is approximately RMB 548 million. It was further announced that, after careful and careful consideration, H+E Pharma and S-Tec (each are intercompany)
Analysis
Price Target
No Data
